pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Novo Nordisk Inc

updated 5mo ago

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.

community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval78 co-mentions · 39 sources
  • drugVICTOZA59 co-mentions · 30 sources
  • drugLIRAGLUTIDE30 co-mentions · 30 sources
  • drugSaxenda30 co-mentions · 30 sources
  • drugOzempic23 co-mentions · 4 sources
  • drugWegovy23 co-mentions · 4 sources
  • drugWegovy Pill22 co-mentions · 3 sources
  • drugSOGROYA18 co-mentions · 9 sources
pipeline
16
marketed
15
phase 3
0
catalysts ytd
4
approvals ytd
3
recalls ytd
0

Pipeline(16)

view full pipeline →
pipeline depth16 products
Marketed: 15Unknown: 1
15Marketed1Unknown
Marketed
(estradiol + norethindrone)
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/…
Marketed
(insulin aspart + insulin aspart protamine)
Type 1 Diabetes (Juvenile Diabetes)
Marketed
(insulin degludec + liraglutide)
Type 2 Diabetes
Marketed
(insulin human + insulin isophane)
Type 1 Diabetes (Juvenile Diabetes)
Marketed
Fiasp
Type 1 Diabetes (Juvenile Diabetes)
Marketed
Rybelsus
Cardiovascular Risk Factors
Marketed
Saxenda
Obesity
Marketed
Wegovy Pill
type 2 diabetes, cardiovascular risk reduction
Marketed
coagulation factor IX (recombinant), glycopegylated LA
Hemophilia B (Factor IX Deficiency)
Marketed
coagulation factor XIII A-subunit (recombinant)
Fibrin Stabilizing Factor Deficiency (Factor XIII Deficie…
Marketed
concizumab
Hemophilia A (Factor VIII Deficiency)
Marketed
dasiglucagon
Hypoglycemia

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Novo Nordisk Inc jobs →

News

  • STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity
    How obesity medications may become the next big battleground over access to medicines in lower-income countries.
    stat · 17h ago
  • AstraZeneca, Calidi, Tempest make significant workforce cuts
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 17h ago
  • Novo’s CagriSema drives more than 20% weight loss at lower doses
    As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed in…
    biospace · 20h ago
  • Their loss, our gain? Canada makes its case to Europe amid U.S. instability
    Companies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners.
    biospace · 21h ago
  • Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
    ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…
    biospace · 3d ago
  • Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
    With 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.
    biospace · 4d ago
  • FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
    Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.
    biospace · 7d ago
  • Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
    If approved, the oral GLP-1 would be Eli Lilly’s second marketed drug for obstructive sleep apnea after the GIP/GLP-1 injectable Zepbound secured the first approval in the space in December 2024.
    biospace · 7d ago
  • STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
    The FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that's sometimes referred to as an "eye stroke."
    stat · 7d ago
  • Merck’s MASH hopeful efinopegdutide wins in mid-stage study
    Merck & Co. revealed results from a mid-stage clinical trial showing its GLP-1 and glucagon receptor co-agonist efinopegdutide resolved cases of MASH compared with placebo without worsening liver f…
    fiercebiotech · 7d ago
view all news mentions →
identifiers
source
globaldata
top tags
Type 2 Diabetes7Obesity2Cardiology1
mentioned in
10news items
entity-linker matched
Data sources
openFDA
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?